These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9033635)

  • 1. Reduction in the duration of myelotoxicity associated with radioimmunotherapy with infusions of the hemoregulatory peptide, HP5b in mice.
    Alisauskas RM; Goldenberg DM; Sharkey RM; Blumenthal RD
    Int J Cancer; 1997 Jan; 70(3):323-9. PubMed ID: 9033635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelosuppressive changes from single or repeated doses of radioantibody therapy: effect of bone marrow transplantation, cytokines, and hematopoietic suppression.
    Blumenthal RD; Alisauskas R; Lew W; Sharkey RM; Goldenberg DM
    Exp Hematol; 1998 Aug; 26(9):859-68. PubMed ID: 9694507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine intervention permits dose escalation of radioantibody. An analysis of myelostimulation by bolus versus continuous infusion of IL-1/GM-CSF.
    Blumenthal RD; Sharkey RM; Forman D; Wong G; Goldenberg DM
    Cancer; 1994 Feb; 73(3 Suppl):1083-92. PubMed ID: 8306251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of hematotoxic side effects of cytostatic drugs in mice by a synthetic hemoregulatory peptide.
    Paukovits WR; Guigon M; Binder KA; Hergl A; Laerum OD; Schulte-Hermann R
    Cancer Res; 1990 Jan; 50(2):328-32. PubMed ID: 2295072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect stimulation of hemopoiesis by hemoregulatory peptide (HP5b) dimer in murine long-term bone marrow cultures.
    Veiby OP; Løvhaug D; Fjerdingstad H; Engelsen SJ
    Exp Hematol; 1992 Feb; 20(2):192-5. PubMed ID: 1544388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection from arabinofuranosylcytosine and n-mustard-induced myelotoxicity using hemoregulatory peptide pGlu-Glu-Asp-Cys-Lys monomer and dimer.
    Paukovits WR; Moser MH; Binder KA; Paukovits JB
    Blood; 1991 Mar; 77(6):1313-9. PubMed ID: 2001454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo modulation of hematopoiesis by a novel hematoregulatory peptide.
    Pelus LM; King AG; Broxmeyer HE; DeMarsh PL; Petteway SR; Bhatnagar PK
    Exp Hematol; 1994 Mar; 22(3):239-47. PubMed ID: 8112423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemoregulatory peptide (HP5b) dimer effects on normal and malignant cells in culture.
    Frostad S; Kalland T; Aakvaag A; Laerum OD
    Stem Cells; 1993 Jul; 11(4):303-11. PubMed ID: 8401253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of haemoregulatory peptides (pEEDCK monomer and dimer) for reduction of cytostatic drug induced haemopoietic damage.
    Paukovits WR; Moser MH; Binder KA; Paukovits JB
    Cancer Treat Rev; 1990 Sep; 17(2-3):347-54. PubMed ID: 2272050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of hematopoietic stem cell proliferation by hemoregulatory peptide pyroGlu-Glu-Asp-Cys-Lys (pEEDCK) provides protection against short-term neutropenia and long-term damage.
    Paukovits WR; Moser MH; Rutter R; Paukovits JB
    Ann N Y Acad Sci; 1991; 628():92-104. PubMed ID: 2069326
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of enriched stem cells in vivo and in vitro by the hemoregulatory peptide SK&F108636.
    Veiby OP; LoCastro S; Bhatnagar P; Olsen WM
    Stem Cells; 1996 Mar; 14(2):215-24. PubMed ID: 8991541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor intervention to reduce myelosuppression.
    Blumenthal RD; Sharkey RM; Goldenberg DM
    J Natl Cancer Inst; 1992 Mar; 84(6):399-407. PubMed ID: 1538418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dimer of hemoregulatory peptide (HP5B) stimulates mouse and human myelopoiesis in vitro.
    Laerum OD; Sletvold O; Bjerknes R; Eriksen JA; Johansen JH; Schanche JS; Tveterås T; Paukovits WR
    Exp Hematol; 1988 May; 16(4):274-80. PubMed ID: 3258825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the hemoregulatory peptide (pEEDCK)2 (pyroGlu-Glu-Asp-Cys-Lys)2 and MIP-1alpha is reduced in bone marrow cultures from patients with chronic myeloid leukemia (CML).
    Karlic H; Louda N; Pfeilstöcker M; Keil F; Lohninger A; Pittermann E; Paukovits J
    Stem Cells; 2001; 19(4):321-8. PubMed ID: 11463952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a hemoregulatory peptide (HP5b) on erythroid and myelopoietic colony formation in vitro.
    Kreja L; Hågå P; Muller-Bérat N; Laerum OD; Sletvold O; Paukovits WR
    Scand J Haematol; 1986 Aug; 37(2):79-86. PubMed ID: 3764340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hemoregulatory peptide pEEDCK may inhibit stem cell proliferation via hydropathic binding to antisense sequence motifs in interleukin-11 and other growth factors.
    Paukovits JB; Rutter R; Ganglberger E; Karlic HI; Marian B; Paukovits WR
    Mol Pharmacol; 1999 Oct; 56(4):665-74. PubMed ID: 10496948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of timing of radioimmunotherapy after granulocyte colony-stimulating factor administration for peripheral blood stem cell harvest.
    Juweid ME; Blumenthal RD; Lew W; Hajjar G; Rubin AD; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3337s-3342s. PubMed ID: 10541383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow transplantation.
    Blumenthal RD; Sharkey RM; Forman D; Wong G; Hess J; Goldenberg DM
    Exp Hematol; 1995 Sep; 23(10):1088-97. PubMed ID: 7656929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo and in vitro effects of cytokines and the hemoregulatory peptide dimer (pEEDCK)2 (pyroGlu-Glu-Asp-Cys-Lys)2 on G alpha16-positive hematopoiesis.
    Pfeilstöcker M; Karlic H; Paukovits J; Anzenberger G; Louda N; Salamon J; Mühlberger H; Strobl H; Pittermann E; Heinz R
    Leukemia; 1999 Apr; 13(4):590-4. PubMed ID: 10214866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-oxidant vitamins reduce normal tissue toxicity induced by radio-immunotherapy.
    Blumenthal RD; Lew W; Reising A; Soyne D; Osorio L; Ying Z; Goldenberg DM
    Int J Cancer; 2000 Apr; 86(2):276-80. PubMed ID: 10738257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.